Next Article in Journal
The Application of Mucoadhesive Chitosan Nanoparticles in Nasal Drug Delivery
Previous Article in Journal
Screening of Human CYP1A2 and CYP3A4 Inhibitors from Seaweed In Silico and In Vitro
Open AccessArticle

A New Bioassay Platform Design for the Discovery of Small Molecules with Anticancer Immunotherapeutic Activity

1
Bio-Organic Chemistry Unit, CNR-Institute of Biomolecular Chemistry, Via Campi Flegrei 34, 80078 Naples, Italy
2
Consorzio Italbiotec, Via Fantoli, 16/15, 20138 Milan, Italy
3
BioSearch Srl., Villa Comunale c/o Stazione Zoologica “A.Dohrn”, 80121 Naples, Italy
4
Internal Medicine, Clinical Immunology and Translational Medicine, University of Genova and IRCCS-Hospital S. Martino, 16132 Genova, Italy
5
Department of Biology, University of Naples Federico II, Via Vicinale Cupa Cintia 21, 80126 Naples, Italy
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Mar. Drugs 2020, 18(12), 604; https://doi.org/10.3390/md18120604
Received: 23 October 2020 / Revised: 18 November 2020 / Accepted: 26 November 2020 / Published: 29 November 2020
Immunotherapy takes advantage of the immune system to prevent, control, and eliminate neoplastic cells. The research in the field has already led to major breakthroughs to treat cancer. In this work, we describe a platform that integrates in vitro bioassays to test the immune response and direct antitumor effects for the preclinical discovery of anticancer candidates. The platform relies on the use of dendritic cells that are professional antigen-presenting cells (APC) able to activate T cells and trigger a primary adaptive immune response. The experimental procedure is based on two phenotypic assays for the selection of chemical leads by both a panel of nine tumor cell lines and growth factor-dependent immature mouse dendritic cells (D1). The positive hits are then validated by a secondary test on human monocyte-derived dendritic cells (MoDCs). The aim of this approach is the selection of potential immunotherapeutic small molecules from natural extracts or chemical libraries. View Full-Text
Keywords: chemical immunology; immunotherapy; dendritic cell; screening guidelines; drug discovery; anticancer; high throughput; bioassay platform chemical immunology; immunotherapy; dendritic cell; screening guidelines; drug discovery; anticancer; high throughput; bioassay platform
Show Figures

Figure 1

MDPI and ACS Style

Gallo, C.; Barra, G.; Saponaro, M.; Manzo, E.; Fioretto, L.; Ziaco, M.; Nuzzo, G.; d’Ippolito, G.; De Palma, R.; Fontana, A. A New Bioassay Platform Design for the Discovery of Small Molecules with Anticancer Immunotherapeutic Activity. Mar. Drugs 2020, 18, 604. https://doi.org/10.3390/md18120604

AMA Style

Gallo C, Barra G, Saponaro M, Manzo E, Fioretto L, Ziaco M, Nuzzo G, d’Ippolito G, De Palma R, Fontana A. A New Bioassay Platform Design for the Discovery of Small Molecules with Anticancer Immunotherapeutic Activity. Marine Drugs. 2020; 18(12):604. https://doi.org/10.3390/md18120604

Chicago/Turabian Style

Gallo, Carmela; Barra, Giusi; Saponaro, Marisa; Manzo, Emiliano; Fioretto, Laura; Ziaco, Marcello; Nuzzo, Genoveffa; d’Ippolito, Giuliana; De Palma, Raffaele; Fontana, Angelo. 2020. "A New Bioassay Platform Design for the Discovery of Small Molecules with Anticancer Immunotherapeutic Activity" Mar. Drugs 18, no. 12: 604. https://doi.org/10.3390/md18120604

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop